Importer of Controlled Substances; Notice of Registration, 10312 [2010-4722]

Download as PDF 10312 Federal Register / Vol. 75, No. 43 / Friday, March 5, 2010 / Notices behalf of, Sharp, or any of its affiliated companies, parents, subsidiaries, licensees, contractors, or other related business entities, or successors or assigns; and (2) cease and desist orders prohibiting Sharp Electronics Corp. and Sharp Electronics Manufacturing Co. from conducting any of the following activities in the United States: Importing, selling, marketing, advertising, distributing, offering for sale, transferring (except for exportation), and soliciting U.S. agents or distributors for, LCD devices, including display panels and modules, and LCD televisions or professional displays containing the same that are covered by claims 7 or 8 of the ‘344 patent. On February 12, 2010, complainant Samsung and respondent Sharp filed a joint petition to rescind the remedial orders under Commission Rule 210.76(a)(1) on the basis of a settlement agreement between the parties. The parties asserted that their settlement agreement constitutes ‘‘changed conditions of fact or law’’ sufficient to justify rescission of the order under Commission Rule 210.76(a)(1), 19 CFR 210.76(a)(1). The IA did not oppose the joint petition. Having reviewed the parties’ submissions, the Commission has determined that the settlement agreement satisfies the requirement of Commission Rule 210.76(a)(1), 19 CFR 210.76(a)(1), that there be changed conditions of fact or law. The Commission therefore has issued an order rescinding the limited exclusion order and cease and desist orders previously issued in this investigation. This action is taken under the authority of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337) and section 210.76(a)(1) of the Commission’s Rules of Practice and Procedure (19 CFR 210.76(a)(1)). Issued: March 1, 2010. By order of the Commission. Marilyn R. Abbott, Secretary to the Commission. DEPARTMENT OF JUSTICE Drug Enforcement Administration erowe on DSK5CLS3C1PROD with NOTICES Dated: February 26, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. BILLING CODE 4410–09–P Importer of Controlled Substances; Notice of Registration By Notice dated October 20, 2009, and published in the Federal Register on October 28, 2009 (74 FR 55583), Formulation Technologies LLC., 11501 Jkt 220001 Dated: February 26, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2010–4773 Filed 3–4–10; 8:45 am] DEPARTMENT OF JUSTICE Drug Enforcement Administration [FR Doc. 2010–4722 Filed 3–4–10; 8:45 am] BILLING CODE 4410–09–P Importer of Controlled Substances Notice of Registration DEPARTMENT OF JUSTICE By Notice dated October 21, 2009, and published in the Federal Register on October 28, 2009 (74 FR 55584), Hospira Inc., 1776 North Centennial Drive, McPherson, Kansas 67460–1247, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Remifentanil (9739), a basic class of controlled substance listed in schedule II. The company plans to import Remifentanil for use in dosage form manufacturing. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Hospira Inc. to import the basic class of controlled substance is consistent with the public interest, and with United States obligations under international Drug Enforcement Administration By Notice dated November 23, 2009, and published in the Federal Register on December 2, 2009 (74 FR 63155), Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule II: BILLING CODE 7020–02–P 14:45 Mar 04, 2010 The company plans to import the basic classes of controlled substances for manufacture of active pharmaceutical ingredients for sale to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Cambrex Charles City, Inc. to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Cambrex Charles City, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Importer of Controlled Substances Notice of Registration [FR Doc. 2010–4692 Filed 3–4–10; 8:45 am] VerDate Nov<24>2008 Domain Drive, Suite 130, Austin, Texas 78758, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Fentanyl (9801), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance for analytical characterization, secondary packaging, and for distribution to clinical trial sites. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Formulation Technologies LLC., to import the basic class of controlled substance is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Formulation Technologies LLC., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Drug Schedule Opium, raw (9600) ....................... Poppy Straw Concentrate (9670) PO 00000 Frm 00109 Fmt 4703 Sfmt 4703 II II E:\FR\FM\05MRN1.SGM 05MRN1

Agencies

[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Page 10312]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-4722]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Registration

    By Notice dated October 20, 2009, and published in the Federal 
Register on October 28, 2009 (74 FR 55583), Formulation Technologies 
LLC., 11501 Domain Drive, Suite 130, Austin, Texas 78758, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as an importer of Fentanyl (9801), a basic class of 
controlled substance listed in schedule II.
    The company plans to import the listed controlled substance for 
analytical characterization, secondary packaging, and for distribution 
to clinical trial sites.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and 952(a), and determined that the 
registration of Formulation Technologies LLC., to import the basic 
class of controlled substance is consistent with the public interest, 
and with United States obligations under international treaties, 
conventions, or protocols in effect on May 1, 1971, at this time. DEA 
has investigated Formulation Technologies LLC., to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in 
accordance with 21 CFR 1301.34, the above named company is granted 
registration as an importer of the basic class of controlled substance 
listed.

    Dated: February 26, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-4722 Filed 3-4-10; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.